mdma辅助创伤后应激障碍的团体治疗：新方案的发展

IF 2.9 3区心理学 Q1 PSYCHOLOGY, CLINICAL

Cognitive and Behavioral Practice Pub Date : 2025-06-03 DOI:10.1016/j.cbpra.2025.03.001

Christopher S. Stauffer, Philip Bouleh, Brian T. Anderson

{"title":"mdma辅助创伤后应激障碍的团体治疗：新方案的发展","authors":"Christopher S. Stauffer, Philip Bouleh, Brian T. Anderson","doi":"10.1016/j.cbpra.2025.03.001","DOIUrl":null,"url":null,"abstract":"<div><div>Posttraumatic stress disorder (PTSD) presents unique psychosocial challenges among veterans. Group therapy is used widely in the Veterans Health Administration to treat PTSD, yet further research is needed to optimize group interventions. The integration of group therapy with 3,4-methylenedioxymethamphetamine (MDMA) represents a promising strategy for PTSD recovery given potential synergy between the therapeutic effects of group cohesion and the prosocial effects of MDMA.</div><div>This paper describes the development of a clinical research protocol for a single-arm, open-label study assessing the feasibility, safety, and preliminary effectiveness of MDMA-assisted group therapy in a sample of Veterans diagnosed with PTSD within the veterans Affairs Portland Healthcare System. Enrolled veterans will be assigned to one of 3 cohorts of 4–6 participants each (up to <em>N</em> = 18). In addition to individual and group preparation and integration, this novel protocol includes both individual and group MDMA sessions. PTSD symptom severity will be measured by blinded raters using the Clinician-Administered PTSD Scale for <em>DSM-5</em> at baseline and at 1-month follow-up.</div><div>As the first clinical trial combining group therapy with MDMA-assisted therapy for PTSD, this study will provide valuable data on feasibility, the unique risks and benefits of this model, and preliminary effect sizes for the development of larger randomized controlled trials.</div></div>","PeriodicalId":51511,"journal":{"name":"Cognitive and Behavioral Practice","volume":"32 3","pages":"Pages 339-350"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MDMA-Assisted Group Therapy for PTSD: Development of a Novel Protocol\",\"authors\":\"Christopher S. Stauffer, Philip Bouleh, Brian T. Anderson\",\"doi\":\"10.1016/j.cbpra.2025.03.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Posttraumatic stress disorder (PTSD) presents unique psychosocial challenges among veterans. Group therapy is used widely in the Veterans Health Administration to treat PTSD, yet further research is needed to optimize group interventions. The integration of group therapy with 3,4-methylenedioxymethamphetamine (MDMA) represents a promising strategy for PTSD recovery given potential synergy between the therapeutic effects of group cohesion and the prosocial effects of MDMA.</div><div>This paper describes the development of a clinical research protocol for a single-arm, open-label study assessing the feasibility, safety, and preliminary effectiveness of MDMA-assisted group therapy in a sample of Veterans diagnosed with PTSD within the veterans Affairs Portland Healthcare System. Enrolled veterans will be assigned to one of 3 cohorts of 4–6 participants each (up to <em>N</em> = 18). In addition to individual and group preparation and integration, this novel protocol includes both individual and group MDMA sessions. PTSD symptom severity will be measured by blinded raters using the Clinician-Administered PTSD Scale for <em>DSM-5</em> at baseline and at 1-month follow-up.</div><div>As the first clinical trial combining group therapy with MDMA-assisted therapy for PTSD, this study will provide valuable data on feasibility, the unique risks and benefits of this model, and preliminary effect sizes for the development of larger randomized controlled trials.</div></div>\",\"PeriodicalId\":51511,\"journal\":{\"name\":\"Cognitive and Behavioral Practice\",\"volume\":\"32 3\",\"pages\":\"Pages 339-350\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cognitive and Behavioral Practice\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1077722925000227\",\"RegionNum\":3,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cognitive and Behavioral Practice","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1077722925000227","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 0

摘要

创伤后应激障碍（PTSD）在退伍军人中表现出独特的社会心理挑战。团体治疗在退伍军人健康管理局被广泛用于治疗PTSD，但需要进一步的研究来优化团体干预。考虑到群体凝聚力的治疗效果与MDMA的亲社会效应之间的潜在协同作用，将团体治疗与3,4-亚甲基二氧甲基苯丙胺(3,4-亚甲基二氧甲基苯丙胺（MDMA）结合起来是一种很有前景的创伤后应激障碍康复策略。本文描述了一项单臂、开放标签研究的临床研究方案的发展，该研究评估了mdma辅助团体治疗在波特兰退伍军人事务医疗系统诊断为PTSD的退伍军人样本中的可行性、安全性和初步有效性。招募的退伍军人将被分配到3个队列中的一个，每个队列4-6名参与者（最多N = 18）。除了个人和团体的准备和整合，这个新的协议包括个人和团体MDMA会议。在基线和1个月的随访中，使用DSM-5临床应用PTSD量表由盲法评分者测量PTSD症状严重程度。作为首个将群体治疗与mdma辅助治疗相结合的PTSD临床试验，本研究将为该模型的可行性、独特的风险和益处以及开展更大规模随机对照试验的初步效应量提供有价值的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

MDMA-Assisted Group Therapy for PTSD: Development of a Novel Protocol

Posttraumatic stress disorder (PTSD) presents unique psychosocial challenges among veterans. Group therapy is used widely in the Veterans Health Administration to treat PTSD, yet further research is needed to optimize group interventions. The integration of group therapy with 3,4-methylenedioxymethamphetamine (MDMA) represents a promising strategy for PTSD recovery given potential synergy between the therapeutic effects of group cohesion and the prosocial effects of MDMA.

This paper describes the development of a clinical research protocol for a single-arm, open-label study assessing the feasibility, safety, and preliminary effectiveness of MDMA-assisted group therapy in a sample of Veterans diagnosed with PTSD within the veterans Affairs Portland Healthcare System. Enrolled veterans will be assigned to one of 3 cohorts of 4–6 participants each (up to N = 18). In addition to individual and group preparation and integration, this novel protocol includes both individual and group MDMA sessions. PTSD symptom severity will be measured by blinded raters using the Clinician-Administered PTSD Scale for DSM-5 at baseline and at 1-month follow-up.

As the first clinical trial combining group therapy with MDMA-assisted therapy for PTSD, this study will provide valuable data on feasibility, the unique risks and benefits of this model, and preliminary effect sizes for the development of larger randomized controlled trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cognitive and Behavioral Practice PSYCHOLOGY, CLINICAL-

CiteScore

4.80

自引率

3.40%

发文量

118

审稿时长

84 days

期刊介绍： Cognitive and Behavioral Practice is a quarterly international journal that serves an enduring resource for empirically informed methods of clinical practice. Its mission is to bridge the gap between published research and the actual clinical practice of cognitive behavior therapy. Cognitive and Behavioral Practice publishes clinically rich accounts of innovative assessment and diagnostic and therapeutic procedures that are clearly grounded in empirical research. A focus on application and implementation of procedures is maintained.